logo
  

Novartis Issues Update On Radioligand Therapy Production

Novartis (NVS) said, in early June, the company restarted radioligand therapy production at its sites in Ivrea, Italy, and Millburn, New Jersey, and resumed delivery of doses to patients in a phased approach. Novartis expects that product supply may be initially limited.

The company has also restarted screening and enrollment for clinical trials with 177Lu-PSMA-617 in the US, in most countries globally, and clinical trials with Lutathera in the US and Canada.

Novartis said it is investing in the expansion of radioligand therapy production capabilities in both Millburn and Ivrea, as well as building a new radioligand manufacturing facility in Indianapolis, Indiana that will be operational in 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The US Centers for Disease Control and Prevention or CDC has ended recommendations for social distancing and quarantine with a view to minimize covid-19's impact on persons, communities, and health care systems. The agency also ended recommendation for test-to-stay in schools, CNN noted. Healthcare major Johnson & Johnson, which is in the middle of a talcum powder fiasco, said it is discontinuing talc-based JOHNSON'S Baby Powder globally in 2023. The company plans to transition to an all cornstarch-based baby powder portfolio. According to the company, the commercial decision to use cornstarch in all its baby powder products was made after conducting an assessment of its portfolio Walt Disney's streaming service Disney+ is rolling out its much-anticipated new ad-supported subscription plan for Disney+ in the U.S. as part of its bid to stem the loss and make its streaming business profitable after the services posted a hefty operating loss of more than $1 billion in the third quarter. It is also raising pricing for its bundled subscription plans with Hulu, ESPN+ and live TV.
Follow RTT